Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for more treatment modalities remains, as patients who are refractory to proteasome inhibitors, immunomodul...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Rebecca, Morphey, Ashley, Diaz, Felicia, Chen, Jessica, Razmandi, Azadeh, Richards, Tiffany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258852/
https://www.ncbi.nlm.nih.gov/pubmed/37313276
http://dx.doi.org/10.6004/jadpro.2023.14.4.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258852/
https://www.ncbi.nlm.nih.gov/pubmed/37313276
http://dx.doi.org/10.6004/jadpro.2023.14.4.4

Ejemplares similares